X

Trial Profile

A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 15 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camptothecin (Primary) ; Topotecan
Indications Small cell lung cancer
Focus Therapeutic Use

Most Recent Events

07 Aug 2017 Planned End Date changed from 1 May 2017 to 1 Nov 2017.
16 Jun 2016 Status changed from active, no longer recruiting to discontinued due to lack of activity and slow accrual.
18 Jun 2015 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com